We must learn from the HIV epidemic and ensure that affordable prices are in place so that the millions with hepatitis C infection can get new drugs that appear to be a cure. The leader of the pack is Gilead’s sofosbuvir, licensed in Europe in November and the following month in the US. Janssen and Bristol Myers-Squibb are hard on their heels. The complete article is available here
WHO Calls For High-Priced Drugs For Millions With Hepatitis C
by Richard Knox click here